# AQVESME™ (mitapivat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mitapivat

> The PDUFA target action date for AQVESME™ (mitapivat), sponsored by AGIOS PHARMACEUTICALS, INC. (AGIO), is February 1, 2027, for sickle cell disease. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the AQVESME™ (mitapivat) PDUFA date?

The PDUFA target action date for AQVESME™ (mitapivat), sponsored by AGIOS PHARMACEUTICALS, INC. (AGIO), is February 1, 2027, for sickle cell disease. Status: scheduled. Press release filed with the SEC (EX-99): "•New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA" Last confirmed November 5, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/mitapivat)

Source: Press release filed with the SEC (EX-99), accession 0001439222-26-000129, https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/mitapivat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | AQVESME™ (mitapivat) |
| Codes | AG-348 |
| Sponsor | AGIOS PHARMACEUTICALS, INC. (AGIO) https://sec-api.dev/companies/agio/catalysts |
| Indications | [sickle cell disease](https://sec-api.dev/indications/sickle-cell-disease), anemia in adults with alpha- or beta-thalassemia, regardless of transfusion burden, anemia in adults with alpha- or beta-thalassemia, non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, Non-Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Alpha-Thalassemia |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### February 13, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-02-13, last confirmed 2025-02-13.
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000007): "◦Reported in a separate press release today, positive topline results from the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/agio-021325xfyxex991earnin.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-13, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000034): "- Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 -" https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-050125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000007): "- Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 -" https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/agio-021325xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000114): "◦Topline results from the RISE UP Phase 3 trial of mitapivat in sickle cell disease are expected by year-end, potentially supporting a U.S. commercial launch in 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000087): "•Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026" https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000087): "▪Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm

### October 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Sickle Cell Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05031780 (A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT05031780

### Dec 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: anemia in adults with alpha- or beta-thalassemia.
- First seen 2026-01-12, last confirmed 2026-02-12.
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000023): "◦In December 2025, the U.S. Food and Drug Administration (FDA) approved AQVESME as the only medicine for the treatment of anemia in adults with alpha- or beta-thalassemia, regardless of transfusion burden." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-21226xfyxex991earning.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000018): "-In December 2025, the U.S. Food and Drug Administration (FDA) approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-011226xprxex991.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-04-29, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000071): "Agios expects to report topline results from its Phase 2b trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-04-29, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000071): "•Company plans to submit mitapivat sNDA for sickle cell disease in the second quarter of 2026" https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000071): "The company now plans to submit an sNDA for mitapivat in sickle cell disease in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-04-29, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000071): "Agios expects to report topline results from its Phase 2 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm

### November 1, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-07-30, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000115): "•sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026" https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm
- SEC Form 10-Q (accession 0001439222-26-000131): "We submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000131/agio-20260930.htm
- SEC Form 10-Q (accession 0001439222-26-000131): "We submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000131/agio-20260930.htm
- SEC Form 10-Q (accession 0001439222-26-000118): "We submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm
- SEC Form 10-Q (accession 0001439222-26-000118): "We submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000115): "The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA's accelerated approval pathway, is November 1, 2026." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm

### February 1, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: sickle cell disease.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000129): "•New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA" https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000129): "Our conviction in mitapivat for patients with sickle cell disease is grounded in the robust efficacy and safety data generated to date and we are launch-ready ahead of our PDUFA goal date of February 1, 2027." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-26-000129): "•Agios announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its mitapivat sickle cell disease supplemental New Drug Application (sNDA) by three months, from November 1, 2026, to February 1, 2027." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm
- SEC Form 10-Q (accession 0001439222-26-000131): "The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000131/agio-20260930.htm
- SEC Form 10-Q (accession 0001439222-26-000131): "Our response constituted a major amendment to the mitapivat sNDA, resulting in an extension of our PDUFA goal date to February 1, 2027." https://www.sec.gov/Archives/edgar/data/1439222/000143922226000131/agio-20260930.htm

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07517133 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07517133

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07517133 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07517133

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07506863 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07506863

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07506863 (A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07506863

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Sickle Cell Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07656415 (A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07656415

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Sickle Cell Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07656415 (A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07656415

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mitapivat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AQVESME™ (mitapivat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mitapivat

```bibtex
@misc{secapidev_pdufa_mitapivat_20261116,
  title        = {AQVESME™ (mitapivat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mitapivat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mitapivat_20261116","title":"AQVESME™ (mitapivat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mitapivat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
